Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Analysis of First Line Therapy Criteria Responses in a Cohort of 1,300 Relapsing Remitting MS Patients
Multiple Sclerosis
P9 - Poster Session 9 (12:00 PM-1:00 PM)
9-022

 To identify the main predictors of first line treatments failure and prognosis in a cohort of patients with RRMS.

Many studies focusing on prognostic factors in patients with clinically isolated syndrome have been published. Male gender, late age of onset, multifocal relapses, sequelae after the first event, oligoclonal bands (OCB +), and MRI features are prognostic factors.
Retrospective study from 3 French MS centers (Strasbourg, Marseille, Montpellier). Data were extracted from the French MS databank (EDMUS). Inclusion criteria : a) patients with RRMS criteria, b) first treatment consisting of immunomodulatory treatment (ie: first line). Analysis criteria included : sex, age and EDSS score at the treatment, relapse rate during the year (AAR) before the treatment, OCB +, MR features (high lesion load, ie: > 9 lesions,  posterior fossa involvement, gadolinium enhancement, spinal cord involvement).  Primary endpoint : rate of patients switching to 2nd line therapy. Secondary endpoints :  rate of relapses, EDSS score at year 2 and 5. Statistical analysis used Kaplan Meier and Cox model.

1300 RR MS patients were included : F:971 / M:329 ; mean age of onset : 31.8 yo (24-39), mean age at the treatment (34.7, range 27-42). Mean follow : 10.96 years (range : 6.17 – 14.87). Mean EDSS score at the treatment: 1.5 (range : 0 – 2). CSF results: 111 (12.59 %)  OCB-, 771 (87.41 %) OCB +. ARR before the treatment 1.26 (± 0.87);  0.36 (± 1.23) after.

At 2, 5, 10 and 15 years of treatment, 87.5% (N=1072),  69.7% (N=672), 50.3% (N=273) and 37.25% (N=93) of patients remained on 1st line therapy.

First line failure was related with: age of onset  < 30 yo (p<0.0001), ARR before treatment (p=0.036), EDSS score > 2  (p<0.0001), OCB + (p=0.029), Gd+ (p=0.005), spinal cord involvement (p=0 .043).

This univariate analysis determined first line treatment failure. Multivariate analysis will be presented at the conference.
Authors/Disclosures
Pierre Labauge, MD
PRESENTER 		Dr. Labauge has nothing to disclose.
Jerome De Seze Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma. Jerome De Seze has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pharma.
Jean Pelletier, MD, PhD (Dpt of Neurology, CHU Timone) Dr. Pelletier has nothing to disclose.
Clarisse Carra-Dalliere No disclosure on file
No disclosure on file
No disclosure on file
Kevin Bigaut Kevin Bigaut has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Kevin Bigaut has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche.
Adil Maarouf Adil Maarouf has nothing to disclose.
Xavier Ayrignac Xavier Ayrignac has nothing to disclose.
No disclosure on file